Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4818558

CC(C)Cn1cnc2cnc3ccccc3c21.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 3/20 0.58
PDE4D Q08499 2/20 0.58
POLB P06746 2/20 0.58
HTR2A P28223 2/20 0.58
HTR2B P41595 2/20 0.58
LMNA P02545 1/20 0.58
HRH2 P25021 1/20 0.58
ADRA1D P25100 1/20 0.58
ADORA2A P29274 1/20 0.58
ADRA1A P35348 1/20 0.58
NUDT1 P36639 1/20 0.58
KCNH2 Q12809 1/20 0.58
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
APAF1 O14727 1/20 0.40
HTR2C P28335 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564029 0.98 TLR7 (0.59) TLR7PDE4DPOLBHTR2AHTR2B
SCHEMBL29379266 0.98 TLR7 (0.59) TLR7PDE4DPOLBHTR2AHTR2B
Hydrochloric Acid SCHEMBL5435065 0.97 TLR7 (0.58) TLR7PDE4DPOLBHTR2AHTR2B
Hydrochloric Acid SCHEMBL9602331 0.96 TLR7 (0.56) TLR7PDE4DPOLBHTR2AHTR2B
Propionic Acid SCHEMBL6726633 0.88 TLR7 (0.53) TLR7PDE4DPOLBHTR2AHTR2B
SCHEMBL10734092 0.88 TLR7 (0.50) TLR7PDE4DPOLBHTR2AHTR2B
SCHEMBL10727888 0.87 TLR7 (0.47) TLR7PDE4DPOLBHTR2AHTR2B
Sarcosine SCHEMBL3196280 0.85 TLR7 (0.50) TLR7PDE4DPOLBHTR2AHTR2B
Toluic Acid SCHEMBL6723514 0.83 TLR7 (0.48) TLR7PDE4DPOLBHTR2AHTR2B
SCHEMBL9601955 0.81 SMN1; SMN2 (0.42) TLR7PDE4DPOLBHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100372847-C Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-C] quinolin-4-cyano and 1H-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARMA (HU) 2008-03-05 CN disclosed
US-7335772-B2 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2008-02-26 US disclosed
US-7335772-B2 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2008-02-26 US disclosed
US-7166721-B2 Preparation of 1H-imidazo[4,5-C] quinolin 4-amines via novel 1H-imidazo[4,5-c] quinolin 4-cyano and 1H-imidazo[4,5-c] quinolin 4-carboxamide intermediates TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) 2007-01-23 US disclosed
US-7153967-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2006-12-26 US disclosed
CN-1684963-A Preparation of 1H-imidazo [4, 5-C ] quinolin-4-amines via novel 1H-imidazo [4, 5-C ] quinolin-4-cyano and 1H-imidazo [4, 5-C ] quinolin-4-carboxamide intermediates TEVA PHARMA (HU) 2005-10-19 CN disclosed
US-20050119294-A1 Preparation of 1H-imidazo [4,5-c] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates BIOGAL GYOGYSZERGYAR RT. 2005-06-02 US disclosed
US-20050119294-A1 Preparation of 1H-imidazo [4,5-c] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates BIOGAL GYOGYSZERGYAR RT. 2005-06-02 US disclosed
US-20050113404-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates BIOGAL GYOGYSZERGYAR RT. 2005-05-26 US disclosed
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARAMCEUTICAL INDUSTRIES LTD TO BIOGAL GYOGYSZERGYAR RT. 2005-05-12 US disclosed
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARAMCEUTICAL INDUSTRIES LTD TO BIOGAL GYOGYSZERGYAR RT. 2005-05-12 US disclosed
US-6852861-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates BIOGAL GYOGYSZERGYAR RT. (HU) 2005-02-08 US disclosed
US-20040138459-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates KDM4C, P2RX4, IL4 TLR7 4/4885PDE4D 578/4885POLB 1589/4885
US-20050113404-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TLR7, IL4, P2RY4 TLR7 1/4885PDE4D 458/4885POLB 1630/4885
US-20040138459-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TLR7, IL4, P2RY4 TLR7 1/4885PDE4D 458/4885POLB 1630/4885
US-20050119294-A1 Preparation of 1H-imidazo [4,5-c] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates KDM4C, IFNAR1, P2RX4 TLR7 8/4885PDE4D 559/4885POLB 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.